<?xml version="1.0" encoding="UTF-8"?>
<p id="Par44">
 <list list-type="order">
  <list-item>
   <p id="Par45">Disproportionality analyses [
    <xref ref-type="bibr" rid="CR28">28</xref>, 
    <xref ref-type="bibr" rid="CR39">39</xref>, 
    <xref ref-type="bibr" rid="CR40">40</xref>] that concern one or more medicinal products and one ADR or more and report at least one statistically significant association as per the threshold for significance adopted by the study authors.
   </p>
  </list-item>
  <list-item>
   <p id="Par46">Systematic reviews with or without meta-analyses, randomized controlled trials, observational studies, or more recent methods for signal detection (e.g. self-controlled case series, active surveillance) as detailed in [
    <xref ref-type="bibr" rid="CR39">39</xref>], in which the original authors explicitly described any detected associations as “signal” in the abstract or full text.
   </p>
  </list-item>
  <list-item>
   <p id="Par47">Qualitative appraisals of individual reports or series of reports of ADRs, by either structured or unstructured methods (e.g. Naranjo’s algorithm, global introspection, and other methods for causality assessment [
    <xref ref-type="bibr" rid="CR17">17</xref>]), that have been indexed as “signals” (e.g. signals from the UMC) or in which the original authors explicitly described one or more findings as “signal” in the abstract or full text.
   </p>
  </list-item>
  <list-item>
   <p id="Par48">Government or agency reports, working papers, and drug bulletins, whose entries have been indexed as signals or which explicitly describe an association between one or more medicinal products/ADRs as “signal” (viz. European Medicines Agency [
    <xref ref-type="bibr" rid="CR47">47</xref>]).
   </p>
  </list-item>
 </list>
</p>
